A systematic review of adverse events following immunization during pregnancy and the newborn period

Vaccine

Volumn 33, Issue 47, 2015, Pages 6453-6465

  Fulton, T Roice ^a   Narayanan, Divya ^a   Bonhoeffer, Jan ^b,c   Ortiz, Justin R ^d   Lambach, Philipp ^d   Omer, Saad B ^a,e,f  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c Brighton Collaboration Foundation   (Switzerland)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f EMORY UNIVERSITY   (United States)

Author keywords

Adverse events; AEFI; Case definitionsm; Maternal immunization; Pregnancy; Vaccine safety

Indexed keywords

CHICKENPOX VACCINE; CHOLERA VACCINE; CYTOMEGALOVIRUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS VACCINE; HERPES SIMPLEX VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; RABIES VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RUBELLA VACCINE; STREPTOCOCCUS VACCINE; TETANUS TOXOID; WART VIRUS VACCINE; YELLOW FEVER VACCINE; VACCINE;

ARTICLE; DISEASE CLASSIFICATION; DISEASE ONTOLOGY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEMALE; FEVER; HUMAN; IMMUNIZATION; INJECTION SITE PAIN; LOW BIRTH WEIGHT; NEWBORN; PREECLAMPSIA; PREGNANCY; PREMATURE LABOR; PRIORITY JOURNAL; RESPIRATORY DISTRESS; SMALL FOR DATE INFANT; SPONTANEOUS ABORTION; STANDARDIZATION; STILLBIRTH; SYSTEMATIC REVIEW; WORLD HEALTH ORGANIZATION; ADVERSE EFFECTS; DISEASE TRANSMISSION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEALTH; PATHOLOGY; POSTMARKETING SURVEILLANCE; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; STANDARDS;

DISEASE TRANSMISSION, INFECTIOUS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GLOBAL HEALTH; HUMANS; IMMUNIZATION; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRODUCT SURVEILLANCE, POSTMARKETING; VACCINES; WORLD HEALTH ORGANIZATION;

EID: 84947966817     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.08.043     Document Type: Article

References (92)

1. WHO WHO fact sheet no. 178: children: reducing mortality 2014, Available at: 〈http://www.who.int/mediacentre/factsheets/fs178/en/〉 (accessed 20 April 2015).
2. WHO Millennium development goal 4: reduce child mortality 2015, Available at: (accessed 20 April 2015).
3. United Nations Millennium declaration 2000, Available at: 〈http://www.un.org/millennium/declaration/ares552e.htm〉 (accessed August 1 2015).
4. WHO WHO fact sheet no. 333: newborns: reducing mortality 2012, Available at: 〈http://www.who.int/mediacentre/factsheets/fs333/en/〉 (accessed 20 April 2015).
5. Jackson L.A., Patel S.M., Swamy G.K., et al. Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women. J Infect Dis 2011, 204:854-863.
6. Madhi S.A., Cutland C.L., Kuwanda L., et al. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med 2014, 371:918-931.
7. Munoz F.M., Bond N.H., Maccato M., et al. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. JAMA: J Am Med Assoc 2014, 311:1760-1769.
8. Ortiz J.R., Englund J.A., Neuzil K.M. Influenza vaccine for pregnant women in resource-constrained countries: a review of the evidence to inform policy decisions. Vaccine 2011, 29:4439-4452.
9. Meeting of the Strategic Advisory Group of Experts on immunization, April 2013-conclusions and recommendations (Geneva). World Health Organization Weekly Epidemiological Record: 17 May 2013, vol. 88, 20 (pp. 201-216). Available at (accessed August 1 2015). http://www.who.int/wer/2013/wer8820/en/.
10. Maternal Influenza Immunization Project Maternal influenza immunization project: building an immunization platform in conjunction with antenatal care in low and middle-income, countries 2014, Available at: 〈http://www.who.int/immunization/research/development/influenza_maternal_immunization/en/〉 (accessed 22 October).
11. Gruber M.F. Global and national initiatives to facilitate studies of vaccines in pregnant women. Clin Infect Dis 2014, 59(Suppl. 7):S395-S399. (an official publication of the Infectious Diseases Society of America).
12. Bednarczyk R.A., Adjaye-Gbewonyo D., Omer S.B. Safety of influenza immunization during pregnancy for the fetus and the neonate. Am J Obstet Gynecol 2012, 207:S38-S46.
13. Keller-Stanislawski B., Englund J.A., Kang G., et al. Safety of immunization during pregnancy: a review of the evidence of selected inactivated and live attenuated vaccines. Vaccine 2014, 32:7057-7064.
14. Fell D.B., Dodds L., MacDonald N.E., Allen V.M., McNeil S. Influenza vaccination and fetal and neonatal outcomes. Expert Rev Vaccines 2013, 12:1417-1430.
15. Bratton K.N., Wardle M.T., Orenstein W.A., Omer S.B. Maternal influenza immunization and birth outcomes of stillbirth and spontaneous abortion: a systematic review and meta-analysis. Clin Infect Dis 2015, 60:e11-e19. (an official publication of the Infectious Diseases Society of America).
16. McMillan M., Porritt K., Kralik D., Costi L., Marshall H. Influenza vaccination during pregnancy: a systematic review of fetal death, spontaneous abortion, and congenital malformation safety outcomes. Vaccine 2015, 33:2108-2117.
17. Bonhoeffer J., Zumbrunn B., Heininger U. Reporting of vaccine safety data in publications: systematic review. Pharmacoepidemiol Drug Saf 2005, 14:101-106.
18. Hashim R., Khatib A.M., Enwere G., et al. Safety of the recombinant cholera toxin B subunit, killed whole-cell (rBS-WC) oral cholera vaccine in pregnancy. PLoS Neglect Trop Dis 2012, 6:e1743.
19. Lehmann D., Pomat W.S., Riley I.D., Alpers M.P. Studies of maternal immunisation with pneumococcal polysaccharide vaccine in Papua New Guinea. Vaccine 2003, 21:3446-3450.
20. Orenstein L.A.V., Orenstein E.W., Teguete I., et al. Background rates of adverse pregnancy outcomes for assessing the safety of maternal vaccine trials in sub-Saharan Africa. PLoS ONE 2012, 7(10):e46638.
21. Quiambao B.P., Nohynek H.M., Kayhty H., et al. Immunogenicity and reactogenicity of 23-valent pneumococcal polysaccharide vaccine among pregnant Filipino women and placental transfer of antibodies. Vaccine 2007, 25:4470-4477.
22. Pasternak B., Svanstrom H., Molgaard-Nielsen D., et al. Risk of adverse fetal outcomes following administration of a pandemic influenza A(H1N1) vaccine during pregnancy. JAMA: J Am Med Assoc 2012, 308:165-174.
23. Nishioka Sde A., Nunes-Araujo F.R., Pires W.P., Silva F.A., Costa H.L. Yellow fever vaccination during pregnancy and spontaneous abortion: a case-control study. Trop Med Int Health: TM & IH 1998, 3:29-33.
24. Heikkinen T., Young J., van Beek E., et al. Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study. Am J Obstet Gynecol 2012, 207:177 e1-e1778.
25. WHO WHO meeting to develop Brighton collaboration definitions of key terms used for monitoring the safety of immunization in pregnancy in mothers and newborn, children 2014, Available at: 〈http://www.who.int/immunization/research/meetings_workshops/maternal_immunization_aefi_july14/en/.〉 (accessed 20 April 2015).
26. Munoz F.M., Weisman L.E., Read J.S., et al. Assessment of safety in newborns of mothers participating in clinical trials of vaccines administered during pregnancy. Clin Infect Dis 2014, 59(Suppl7):S415-S427. (an official publication of the Infectious Diseases Society of America).
27. GAIA Global alignment of immunization safety assessment in pregnancy 2014, Available at: 〈https://brightoncollaboration.org/public/what-we-do/Projects/Gaia.html〉 (accessed 20 April 2015).
28. Abzug M.J., Nachman S.A., Muresan P., et al. Safety and immunogenicity of 2009 pH1N1 vaccination in HIV-infected pregnant women. Clin Infect Dis 2013, 56:1488-1497. (an official publication of the Infectious Diseases Society of America).
29. Adedinsewo D.A., Noory L., Bednarczyk R.A., et al. Impact of maternal characteristics on the effect of maternal influenza vaccination on fetal outcomes. Vaccine 2013, 31:5827-5833.
30. Auffret M., Bene J., Gautier S., Moreau-Crepeaux S., Caron J. Pharmacovigilance monitoring of a cohort of pregnant women vaccinated against influenza A(H1N1) variant virus in the Nord-Pas de Calais region of northern France. Eur J Obst Gynecol Reprod Biol 2013, 170:114-118.
31. Baker C.J., Rench M.A., Edwards M.S., Carpenter R.J., Hays B.M., Kasper D.L. Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus. N Engl J Med 1988, 319:1180-1185.
32. Baker C.J., Rench M.A., McInnes P. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine 2003, 21:3468-3472.
33. Black S.B., Shinefield H.R., France E.K., Fireman B.H., Platt S.T., Shay D. Effectiveness of influenza vaccine during pregnancy in preventing hospitalizations and outpatient visits for respiratory illness in pregnant women and their infants. Am J Perinatol 2004, 21:333-339.
34. Cantu J., Biggio J., Jauk V., Wetta L., Andrews W., Tita A. Selective uptake of influenza vaccine and pregnancy outcomes. J Maternal-fetal Neonat Med 2013, 26:1207-1211. (the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet).
35. Cavalcanti D.P., Salomao M.A., Lopez-Camelo J., Pessoto M.A. Early exposure to yellow fever vaccine during pregnancy. Trop Med Int Health: TM & IH 2007, 12:833-837.
36. Chambers C.D., Johnson D., Xu R., et al. Risks and safety of pandemic H1N1 influenza vaccine in pregnancy: birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants. Vaccine 2013, 31:5026-5032.
37. Chavant F., Ingrand I., Jonville-Bera A.P., et al. The PREGVAXGRIP study: a cohort study to assess foetal and neonatal consequences of in utero exposure to vaccination against A(H1N1)v2009 influenza. Drug Saf 2013, 36:455-465. (an international journal of medical toxicology and drug experience).
38. Christian L.M., Iams J.D., Porter K., Glaser R. Inflammatory responses to trivalent influenza virus vaccine among pregnant women. Vaccine 2011, 29:8982-8987.
39. Conlin A.M., Bukowinski A.T., Sevick C.J., DeScisciolo C., Crum-Cianflone N.F. Safety of the pandemic H1N1 influenza vaccine among pregnant U.S. military women and their newborns. Obstet Gynecol 2013, 121:511-518.
40. Cottin P., Niedrig M., Domingo C. Safety profile of the yellow fever vaccine Stamaril(registered trademark): a 17-year review. Expert Rev Vaccines 2013, 12:1351-1368.
41. da Silva e Sa G.R., Camacho L.A., Stavola M.S., Lemos X.R., Basilio de Oliveira C.A., Siqueira M.M. Pregnancy outcomes following rubella vaccination: a prospective study in the state of Rio de Janeiro, Brazil, 2001-2002. J Infect Dis 2011, 204(Suppl2):S722-S728.
42. Dana A., Buchanan K.M., Goss M.A., et al. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol 2009, 114:1170-1178.
43. De Vries L., van Hunsel F., Cuppers-Maarschalkerweerd B., van Puijenbroek E., van Grootheest K. Adjuvanted A/H1N1 (2009) influenza vaccination during pregnancy: description of a prospective cohort and spontaneously reported pregnancy-related adverse reactions in the Netherlands. Birth Defects Res, A-Clin Mol Teratol 2014, 100(10):731-738.
44. Ergenoglu A.M., Yeniel A.O., Yildirim N., Kazandi M., Akercan F., Sagol S. Rubella vaccination during the preconception period or in pregnancy and perinatal and fetal outcomes. Turkish J Pediatr 2012, 54:230-233.
45. Harjulehto-Mervaala T., Aro T., Hiilesmaa V.K., Hovi T., Saxen H., Saxen L. Oral polio vaccination during pregnancy: lack of impact on fetal development and perinatal outcome. Clin Infect Dis 1994, 18:414-420. (an official publication of the Infectious Diseases Society of America).
46. Huang G., Liu H., Cao Q., Liu B., Pan H., Fu C. Safety of post-exposure rabies prophylaxis during pregnancy: a follow-up study from Guangzhou, China. Hum Vaccines Immunother 2013, 9:177-183.
47. Kallen B., Olausson P.O. Vaccination against H1N1 influenza with Pandemrix((R)) during pregnancy and delivery outcome: a Swedish register study. BJOG 2012, 119:1583-1590. (an international journal of obstetrics and gynaecology).
48. Kharbanda E.O., Vazquez-Benitez G., Lipkind H., Naleway A., Lee G., Nordin J.D. Inactivated influenza vaccine during pregnancy and risks for adverse obstetric events. Obstet Gynecol 2013, 122:659-667.
49. Kharbanda E.O., Vazquez-Benitez G., Shi W.X., et al. Assessing the safety of influenza immunization during pregnancy: the vaccine safety datalink. Am J Obstet Gynecol 2012, 207:S47-S51.
50. Launay O., Krivine A., Charlier C., et al. Low rate of pandemic A/H1N1 2009 influenza infection and lack of severe complication of vaccination in pregnant women: a prospective cohort study. PLoS ONE 2012, 7:e52303.
51. Lin S.Y., Wu E.T., Lin C.H., Shyu M.K., Lee C.N. The safety and immunogenicity of trivalent inactivated influenza vaccination: a study of maternal-cord blood pairs in Taiwan. PLoS ONE 2013, 8(6):e62983.
52. Lin T.H., Lin S.Y., Lin C.H., et al. AdimFlu-S((R)) influenza A (H1N1) vaccine during pregnancy: the Taiwanese Pharmacovigilance Survey. Vaccine 2012, 30:2671-2675.
53. Louik C., Ahrens K., Kerr S., et al. Risks and safety of pandemic H1N1 influenza vaccine in pregnancy: exposure prevalence, preterm delivery, and specific birth defects. Vaccine 2013, 31:5033-5040.
54. Ludvigsson J.F., Zugna D., Cnattingius S., et al. Influenza H1N1 vaccination and adverse pregnancy outcome. Eur J Epidemiol 2013, 28:579-588.
55. Mackenzie I.S., MacDonald T.M., Shakir S., et al. Influenza H1N1 (swine flu) vaccination: a safety surveillance feasibility study using self-reporting of serious adverse events and pregnancy outcomes. Br J Clin Pharmacol 2012, 73:801-811.
56. Makris M.C., Polyzos K.A., Mavros M.N., Athanasiou S., Rafailidis P.I., Falagas M.E. Safety of hepatitis B, pneumococcal polysaccharide and meningococcal polysaccharide vaccines in pregnancy: a systematic review. Drug Saf 2012, 35:1-14. (an international journal of medical toxicology and drug experience).
57. Moro P.L., Broder K., Zheteyeva Y., et al. Adverse events following administration to pregnant women of influenza A (H1N1) 2009 monovalent vaccine reported to the vaccine adverse event reporting system. Am J Obstet Gynecol 2011, 205:473 e1-e4739.
58. Moro P.L., Broder K., Zheteyeva Y., et al. Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the vaccine adverse event reporting system, 1990-2009. Am J Obstet Gynecol 2011, 204:146 e1-e1467.
59. Moro P.L., Museru O.I., Broder K., et al. Safety of influenza A (H1N1) 2009 live attenuated monovalent vaccine in pregnant women. Obstet Gynecol 2013, 122:1271-1278.
60. Moro P.L., Museru O.I., Niu M., Lewis P., Broder K. Reports to the vaccine adverse event reporting system after hepatitis A and hepatitis AB vaccines in pregnant women. Am J Obstet Gynecol 2014, 210:561 e1-e5616.
61. Moro P.L., Tepper N.K., Grohskopf L.A., Vellozzi C., Broder K. Safety of seasonal influenza and influenza A (H1N1) 2009 monovalent vaccines in pregnancy. Expert Rev Vaccines 2012, 11:911-921.
62. Munoz F.M., Englund J.A., Cheesman C.C., et al. Maternal immunization with pneumococcal polysaccharide vaccine in the third trimester of gestation. Vaccine 2001, 20:826-837.
63. Munoz F.M., Greisinger A.J., Wehmanen O.A., et al. Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol 2005, 192:1098-1106.
64. Munoz F.M., Piedra P.A., Glezen W.P. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 2003, 21:3465-3467.
65. Naleway A.L., Irving S.A., Henninger M.L., et al. Safety of influenza vaccination during pregnancy: a review of subsequent maternal obstetric events and findings from two recent cohort studies. Vaccine 2014, 32:3122-3127.
66. Nordin J.D., Kharbanda E.O., Benitez G.V., et al. Maternal safety of trivalent inactivated influenza vaccine in pregnant women. Obstet Gynecol 2013, 121:519-525.
67. Nordin J.D., Kharbanda E.O., Vazquez Benitez G., Lipkind H., Vellozzi C., Destefano F. Maternal influenza vaccine and risks for preterm or small for gestational age birth. J Pediatr 2014, 164:1051-1700.
68. Omon E., Damase-Michel C., Hurault-Delarue C., et al. Non-adjuvanted 2009 influenza A (H1N1)v vaccine in pregnant women: the results of a French prospective descriptive study. Vaccine 2011, 29:9649-9654.
69. Oppermann M., Fritzsche J., Weber-Schoendorfer C., et al. A(H1N1)v2009: a controlled observational prospective cohort study on vaccine safety in pregnancy. Vaccine 2012, 30:4445-4452.
70. Pardon F., Vilarino M., Barbero P., et al. Rubella vaccination of unknowingly pregnant women during 2006 mass campaign in Argentina. J Infect Dis 2011, 204(Suppl2):S745-S747.
71. Pass R.F., Zhang C., Evans A., et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 2009, 360:1191-1199.
72. Pasternak B., Svanstrom H., Molgaard-Nielsen D., et al. Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark. BMJ (Clin Res Ed.) 2012, 344:e2794.
73. Pitisuttithum P., Rerks-Ngarm S., Bussaratid V., et al. Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand. PLoS ONE 2011, 6:e27837.
74. Santosham M., Englund J.A., McInnes P., et al. Safety and antibody persistence following Haemophilus influenzae type b conjugate or pneumococcal polysaccharide vaccines given before pregnancy in women of childbearing age and their infants. Pediatr Infect Dis J 2001, 20:931-940.
75. Sato H.K., Sanajotta A.T., Moraes J.C., et al. Rubella vaccination of unknowingly pregnant women: the Sao Paulo experience, 2001. J Infect Dis 2011, 204(Suppl2):S737-S744.
76. Shakib J.H., Korgenski K., Sheng X., Varner M.W., Pavia A.T., Byington C.L. Tetanus, diphtheria, acellular pertussis vaccine during pregnancy: pregnancy and infant health outcomes. J Pediatr 2013, 163:1422-1460.
77. Sheffield J.S., Greer L.G., Rogers V.L., et al. Effect of influenza vaccination in the first trimester of pregnancy. Obstet Gynecol 2012, 120:532-537.
78. Sheffield J.S., Hickman A., Tang J., et al. Efficacy of an accelerated hepatitis B vaccination program during pregnancy. Obstet Gynecol 2011, 117:1130-1135.
79. Sheffield J.S., Munoz F.M., Beigi R.H., et al. Research on vaccines during pregnancy: reference values for vital signs and laboratory assessments. Vaccine 2013, 31:4264-4273.
80. Silveira C.M., Caceres V.M., Dutra M.G., Lopes-Camelo J., Castilla E.E. Safety of tetanus toxoid in pregnant women: a hospital-based case-control study of congenital anomalies. Bull World Health Org 1995, 73:605-608.
81. Suzano C.E., Amaral E., Sato H.K., Papaiordanou P.M. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Vaccine 2006, 24:1421-1426.
82. Talbot E.A., Brown K.H., Kirkland K.B., Baughman A.L., Halperin S.A., Broder K.R. The safety of immunizing with tetanus-diphtheria-acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak. Vaccine 2010, 28:8001-8007.
83. Tavares F., Cheuvart B., Heineman T., Arellano F., Dubin G. Meta-analysis of pregnancy outcomes in pooled randomized trials on a prophylactic adjuvanted glycoprotein D subunit herpes simplex virus vaccine. Vaccine 2013, 31:1759-1764.
84. Tavares F., Nazareth I., Monegal J.S., Kolte I., Verstraeten T., Bauchau V. Pregnancy and safety outcomes in women vaccinated with an AS03-adjuvanted split virion H1N1 (2009) pandemic influenza vaccine during pregnancy: a prospective cohort study. Vaccine 2011, 29:6358-6365.
85. Thomas R.E., Lorenzetti D.L., Spragins W., Jackson D., Williamson T. The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review. Am J Trop Med Hygiene 2012, 86:359-372.
86. Toback S.L., Beigi R., Tennis P., Sifakis F., Calingaert B., Ambrose C.S. Maternal outcomes among pregnant women receiving live attenuated influenza vaccine. Influenza Other Respir Viruses 2012, 6:44-51.
87. Tsai T., Kyaw M.H., Novicki D., Nacci P., Rai S., Clemens R. Exposure to MF59-adjuvanted influenza vaccines during pregnancy-a retrospective analysis. Vaccine 2010, 28:1877-1880.
88. Wilson E., Goss M.A., Marin M., et al. Varicella vaccine exposure during pregnancy: data from 10 years of the pregnancy registry. J Infect Dis 2008, 197(Suppl2):S178-S184.
89. Wise R.P., Salive M.E., Braun M.M., et al. Postlicensure safety surveillance for varicella vaccine. JAMA: J Am Med Assoc 2000, 284:1271-1279.
90. Wright P., Lambert J.S., Gorse G.J., et al. Immunization with envelope MN rgp120 vaccine in human immunodeficiency virus-infected pregnant women. J Infect Dis 1999, 180:1080-1088.
91. Zheteyeva Y., Moro P.L., Yue X., Broder K. Safety of meningococcal polysaccharide-protein conjugate vaccine in pregnancy: a review of the vaccine adverse event reporting system. Am J Obstet Gynecol 2013, 208. 478 e1-6.
92. Zheteyeva Y.A., Moro P.L., Tepper N.K., et al. Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines in pregnant women. Am J Obstet Gynecol 2012, 207. 59 e1-7.